Home / Market News / $EDIT

$EDIT news and market catalysts

The 7 most recent market catalysts affecting $EDIT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 2 high impact 5 bullish 0 bearish Biotechnology
Nov 9, 2026 Corporate Catalyst Neutral Impact 85
Editas Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
Editas Medicine announced its third-quarter 2026 financial results, showing a reduced net loss and increased revenue year-over-year. More significantly, the company presented compe…
Oct 8, 2026 Corporate Catalyst Bullish Impact 65
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
Wells Fargo analyst Yanan Zhu upgraded Editas Medicine (EDIT) from Equal-Weight to Overweight and raised the price target from $4 to $6. This upgrade reflects a more optimistic out…
Oct 8, 2026 Corporate Catalyst Bullish Impact 75
Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
Editas Medicine announced that its Phase 1/2 Strive clinical trial for EDIT-401 has received approval in Australia and is under review in New Zealand. This is a crucial development…
Sep 23, 2026 Corporate Catalyst Bullish Impact 65
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
The filing reports multiple analyst upgrades across different companies. For Editas Medicine (EDIT), Guggenheim upgraded the stock from Neutral to Buy with a $5 price target, a sig…
Sep 23, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (EDIT) from Neutral to Buy and established a $5 price target. This upgrade signals increased confidence from a prom…
Aug 31, 2026 Corporate Catalyst Neutral Impact 55
Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
Editas Medicine filed a mixed shelf offering prospectus, which is a standard regulatory step allowing a company to issue various types of securities (like common stock, preferred s…
Aug 5, 2026 Corporate Catalyst Bullish Impact 92
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
Editas Medicine (EDIT) announced Q2 earnings per share of $(0.15), significantly beating the analyst estimate of $(0.27), and sales of $11.900 million, far exceeding the $2.800 mil…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.